A study of evaluation to the predictive biomarker of Nivolumab in peripheral blood and pleural effusion.
Not Applicable
- Conditions
- previously treated patients with advanced non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000023873
- Lead Sponsor
- Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)With interstitial pneumonia or pulmonary fibrosis on a chest X-ray 2)Clinically significant drug allergy 3)Presencee of other active malignancy 4)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage 5)Positive serum HBs antigen 6)With severe infection, cardiac diseases, diabates, hypertention, other severe complication 7)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. 8)Pregnancy or lactating patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method